{
  "id": 1866769,
  "title": "Piramal Pharma acquires controlling 40 per cent stake in Yapan Bio",
  "url": "https://urgent.news/2026/08/19/piramal-pharma-acquires-controlling-40-per-cent-stake-in-yapan-bio",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-19T04:51:04.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/piramal-pharma-acquires-controlling-40-per-cent-stake-in-yapan-bio-159005.html"
  },
  "original_language": "en",
  "account": "MUMBAI, India, August 19, 2026 - Piramal Pharma Ltd. has finalized its acquisition of a 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics. The cash deal, totaling ₹76 crore ($7.95M USD), brings Piramal Pharma's ownership in Yapan Bio to 74%, effectively making Yapan Bio a subsidiary of Piramal Pharma Solutions (PPS). The transaction, completed on August 18, 2026, is a significant step for Piramal Pharma's plan to expand its presence in the biologics sector.\n\nWith the acquisition, Piramal Pharma will integrate Yapan Bio's advanced large molecule capabilities into its service offerings, enhancing its ability to develop and scale complex biologic therapies more efficiently. Yapan Bio will continue to operate within Piramal Pharma Solutions, PPS, the CDMO arm of Piramal Pharma. The acquisition also strengthens Piramal Pharma's ADCelerate™ platform, a fixed-price, integrated service for Phase I ADC development, which can now accelerate from R&D to GMP in as little as 12 months.\n\nPeter DeYoung, CEO of Piramal Global Pharma, stated, \"This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action. By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet the rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.\"",
  "summary": "Healthcare firm Piramal Pharma completed its purchase of an additional 40 per cent stake in CDMO Yapan Bio on 19 August 2026 to expand vaccine manufacturing",
  "key_points": [
    "Piramal Pharma acquires 40.67% stake in Yapan Bio for ₹76 crore ($7.95M USD).",
    "Acquisition makes Yapan Bio a 74% subsidiary of Piramal Pharma Solutions.",
    "Integration enhances Piramal Pharma's biologics sector presence and ADCelerate™ platform."
  ],
  "editors_take": "Piramal Pharma's acquisition of a controlling stake in Yapan Bio expands its biologics capabilities, integrates large molecule expertise, and accelerates its ADCelerate platform, solidifying its presence in the complex biologics market.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}